Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Discontinuation of product line
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A multicenter study, using prospectively collected, fresh (Category I) and frozen (Category II), residual/leftover nasopharyngeal (NP) swab in UTM/UVT specimens obtained from symptomatic individuals suspected of COVID-19 infection. This study will evaluate the NeuMoDx SARS-CoV-2 Assay's clinical performance on the NeuMoDx 288 and NeuMoDx 96 Molecular Systems.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| NeuMoDx SARS-CoV-2 Assay | Diagnostic Test | The NeuMoDx™ SARS-CoV-2 Assay is an automated, in vitro nucleic acid amplification test intended for the qualitative detection of SARS-CoV-2 RNA in nasopharyngeal (NP) swabs in transport medium obtained from symptomatic individuals suspected of COVID-19 infection. The NeuMoDx SARS-CoV-2 Assay as performed on the NeuMoDx™ 288 Molecular System and NeuMoDx™ 96 Molecular System incorporates automated RNA extraction to isolate target nucleic acids from the specimen and real-time reverse transcription PCR targeting two conserved regions of the SARS-CoV-2 genome. |
| Measure | Description | Time Frame |
|---|---|---|
| Sensitivity as compared to the comparator method | Sensitivity ≥ 95% with a lower bound of the two-sided 95% CI > 90% | Through study completion estimated 9 months |
| Measure | Description | Time Frame |
|---|---|---|
| Specificity | Specificity ≥ 95% with a lower bound of the two-sided 95% CI > 90% | Through study completion estimated 9 months |
Not provided
Inclusion Criteria:
Any de-identified NP swab specimen in transport medium from a symptomatic individual suspected of COVID-19 at the time of collection.
NP swab specimens obtained using a flexible mini-tip flocked swab and collected into 3mL Copan UTM [Cat. No. 305C] or BD UVT [Cat. No. 220531].
Prospective specimens, fresh (Category I) shall be tested within:
Minimum volume of ≥ 2mL.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Symptomatic subjects suspected of COVID-19
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| QIAGEN Gaithersburg, Inc | Manchester | M130BH | United Kingdom |
Not provided
Not provided
Not provided
Not provided
Nasopharyngeal swabs in UTM or UVT